Geron Share Price Today
(NASDAQ: GERN)

Name: Geron Share Price Today (NASDAQ: GERN) - Geron Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Geron share price is $2.57 & ₹222.89 as on 22 Feb 2025, 2.30 'hrs' IST

$2.57

▲

-0.06

(-2.28%)

Market is closed - opens 8 PM, 24 Feb 2025

View live Geron share price in Dollar and Rupees. Guide to invest in Geron stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Geron, along with analyst recommendations, forecasts, and comprehensive financials.

Geron share price movements

Today's Low: $2.56
Today's High: $2.63
$2.57
0.39%
Downside
Day's Volatility :2.48%
Upside
2.1%
52 Weeks Low: $1.64
52 Weeks High: $5.34
$2.57
36.19%
Downside
52 Weeks Volatility :69.29%
Upside
51.87%

Geron (GERN) Returns

Period	Geron Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	-37.32%	1.6%	0.0%
6 Months	-43.64%	-5.8%	0.0%
1 Year	24.15%	-1.0%	0.0%
3 Years	133.64%	15.7%	-9.0%

Geron (GERN) Key Statistics

in dollars & INR

Previous Close	$2.63
Open	$2.635
Today's High	$2.625
Today's Low	$2.56
Market Capitalization	$1.6B
Today's Volume	$8.9M
52 Week High	$5.34
52 Week Low	$1.64
Revenue TTM	$29.5M
EBITDA	$-207.5M
Earnings Per Share (EPS)	$-0.32
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-69.03%

How to invest in Geron Stock (GERN) from India?

It is very easy for Indian residents to invest directly in Geron from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Geron stock in both Indian Rupees (INR) and US Dollars (USD). Search for Geron or GERN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Geron or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Geron shares which would translate to 0.337 fractional shares of Geron as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Geron, in just a few clicks!

Returns in Geron (GERN) for Indian investors in Rupees

The Geron stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Geron investment value today

Current value as on today

₹1,28,804

Returns

₹28,804

(+28.8%)

Returns from Geron Stock

₹24,155 (+24.15%)

Dollar Returns

₹4,649 (+4.65%)

Indian investors sentiment towards Geron (GERN)

-18%

Period: Jan 24, 2025 to Feb 23, 2025. Change in 30 Days versus previous period

Search interest for Geron Stock from India on INDmoney has decreased by -18% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Geron

BlackRock Inc
8.05%
RTW INVESTMENTS, LLC
7.30%
Vanguard Group Inc
5.55%
RA Capital Management, LLC
5.34%
State Street Corp
4.79%
Adage Capital Partners Gp LLC
4.78%

Analyst Recommendation on Geron

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Geron(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Geron Stock (GERN)

What analysts predicted

Upside of 187.51%

Target:

$7.39

Current:

$2.57

Insights on Geron Stock (Ticker Symbol: GERN)

Price Movement
In the last 3 months, GERN stock has moved down by -36.9%
Increasing Revenue
Revenue is up for the last 4 quarters, 23.0K → 28.27M (in $), with an average increase of 85.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -67.38M → -26.44M (in $), with an average increase of 154.8% per quarter
GERN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.0% return, outperforming this stock by 27.9%
Price to Sales
ForGERN every $1 of sales, investors are willing to pay $54.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

GERN Geron Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.1M	↑ 0.09%
Net Income	$-27.0M	↓ 3.22%
Net Profit Margin	-2.5K%	↑ 86.79%

	FY19	Y/Y Change
Revenue	$460.0K	↓ 56.85%
Net Income	$-63.6M	↑ 135.23%
Net Profit Margin	-13.8K%	↓ 11281.0%

	FY20	Y/Y Change
Revenue	$253.0K	↓ 45.0%
Net Income	$-75.6M	↑ 18.98%
Net Profit Margin	-29.9K%	↓ 16069.95%

	FY21	Y/Y Change
Revenue	$1.4M	↑ 450.59%
Net Income	$-121.0M	↑ 59.97%
Net Profit Margin	-8.7K%	↑ 21202.54%

	FY22	Y/Y Change
Revenue	$596.0K	↓ 57.21%
Net Income	$-141.0M	↑ 16.6%
Net Profit Margin	-23.7K%	↓ 14980.42%

	FY23	Y/Y Change
Revenue	$237.0K	↓ 60.23%
Net Income	$-184.1M	↑ 30.56%
Net Profit Margin	-77.7K%	↓ 54027.46%

	Q2 FY23	Q/Q Change
Revenue	$29.0K	↑ 38.1%
Net Income	$-49.2M	↑ 29.29%
Net Profit Margin	-169.7K%	↑ 11556.48%

	Q3 FY23	Q/Q Change
Revenue	$164.0K	↑ 465.52%
Net Income	$-44.8M	↓ 8.98%
Net Profit Margin	-27.3K%	↑ 142428.16%

	Q4 FY23	Q/Q Change
Revenue	$23.0K	↓ 85.98%
Net Income	$-52.0M	↑ 16.0%
Net Profit Margin	-226.0K%	↓ 198653.79%

	Q1 FY24	Q/Q Change
Revenue	$304.0K	↑ 1221.74%
Net Income	$-55.4M	↑ 6.57%
Net Profit Margin	-18.2K%	↑ 207753.52%

	Q2 FY24	Q/Q Change
Revenue	$882.0K	↑ 190.13%
Net Income	$-67.4M	↑ 21.65%
Net Profit Margin	-7.6K%	↑ 10580.59%

	Q3 FY24	Q/Q Change
Revenue	$28.3M	↑ 3105.33%
Net Income	$-26.4M	↓ 60.75%
Net Profit Margin	-93.55%	↑ 7546.25%

	FY18	Y/Y Change
Profit	$-11.7M	↑ 58.13%

	FY19	Y/Y Change
Profit	$460.0K	↓ 103.95%

	FY20	Y/Y Change
Profit	$-49.8M	↓ 10925.87%

	FY21	Y/Y Change
Profit	$610.0K	↓ 101.22%

	FY22	Y/Y Change
Profit	$-272.0K	↓ 144.59%

	FY23	Y/Y Change
Profit	$-123.5M	↑ 45305.51%

	Q2 FY23	Q/Q Change
Profit	$-246.0K	↑ 6.96%

	Q3 FY23	Q/Q Change
Profit	$-29.3M	↑ 11795.12%

	Q4 FY23	Q/Q Change
Profit	$-218.0K	↓ 99.26%

	Q1 FY24	Q/Q Change
Profit	$29.0K	↓ 113.3%

	Q2 FY24	Q/Q Change
Profit	$436.0K	↑ 1403.45%

	Q3 FY24	Q/Q Change
Profit	$28.2M	↑ 6369.95%

	FY18	Y/Y Change
Operating Cash Flow	$-21.0M	↑ 2.2%
Investing Cash Flow	$-77.7M	↓ 438.35%
Financing Cash Flow	$93.0M	↑ 8267.96%

	FY19	Y/Y Change
Operating Cash Flow	$-43.8M	↑ 108.62%
Investing Cash Flow	$27.4M	↓ 135.26%
Financing Cash Flow	$19.5M	↓ 79.03%

	FY20	Y/Y Change
Operating Cash Flow	$-66.7M	↑ 52.07%
Investing Cash Flow	$-105.3M	↓ 484.38%
Financing Cash Flow	$168.3M	↑ 763.36%

	FY21	Y/Y Change
Operating Cash Flow	$-95.6M	↑ 43.37%
Investing Cash Flow	$71.9M	↓ 168.31%
Financing Cash Flow	$48.6M	↓ 71.16%

	FY22	Y/Y Change
Operating Cash Flow	$-127.4M	↑ 33.3%
Investing Cash Flow	$62.1M	↓ 13.73%
Financing Cash Flow	$87.3M	↑ 79.72%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-29.6M	↓ 36.16%
Investing Cash Flow	$-44.4M	↓ 75.13%
Financing Cash Flow	$18.3M	↓ 93.47%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-50.8M	↑ 71.75%
Investing Cash Flow	$-4.7M	↓ 89.39%
Financing Cash Flow	$29.4M	↑ 60.05%

Geron Technicals Summary

Sell

Neutral

Buy

Geron is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Geron (GERN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Geron Corporation	-14.62%	-43.64%	24.15%	133.64%	125.44%
Biontech Se	1.58%	37.14%	28.33%	-20.32%	255.59%
Regeneron Pharmaceuticals, Inc.	3.63%	-41.61%	-29.21%	13.2%	52.94%
Vertex Pharmaceuticals Incorporated	10.15%	0.33%	11.71%	110.26%	108.69%
Alnylam Pharmaceuticals, Inc.	-10.11%	-6.89%	57.94%	61.67%	112.27%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Geron Corporation	NA	NA	-2.38	-0.28	-0.69	-0.3	NA	0.49
Biontech Se	160.8	NA	0.04	-3.29	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	18.16	18.16	1.01	43.09	0.16	0.07	0.01	273.57
Vertex Pharmaceuticals Incorporated	32.84	NA	1.3	18.11	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.59	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Geron Corporation	Buy	$1.6B	125.44%	NA	0.0%
Biontech Se	Buy	$28.3B	255.59%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$76.1B	52.94%	18.16	31.07%
Vertex Pharmaceuticals Incorporated	Buy	$123.3B	108.69%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$32.5B	112.27%	NA	-12.37%

Geron Dividend announcements

Geron Earnings
Geron’s price-to-earnings ratio stands at None
Read More

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Organization	Geron
Employees	141
CEO	Dr. John A. Scarlett M.D.
Industry	Health Technology

Management People of Geron

Name	Title
Dr. John A. Scarlett M.D.	Chairman of the Board, President & CEO
Ms. Michelle J. Robertson	Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer
Dr. Andrew J. Grethlein Ph.D.	Executive VP & COO
Mr. Scott Samuels	Executive VP, Chief Legal Officer & Secretary
Ms. Aron Feingold	Vice President of Investor Relations & Corporate Communications
Ms. Shannon T. Odam	Senior VP & Chief People Officer
Ms. Melissa A. Kelly Behrs	Executive VP of Business Operations & Chief Alliance Officer
Mr. Edward E. Koval	Executive VP & Chief Business Officer
Dr. Faye Feller M.D.	Executive VP & Chief Medical Officer
Mr. James Ziegler M.B.A.	Executive VP & Chief Commercial Officer

Important FAQs about investing in GERN Stock from India :

What is Geron share price today?

Geron share price today stands at $2.57, Open: $2.64 ; Previous Close: $2.63 ; High: $2.63 ; Low: $2.56 ; 52 Week High: $5.34 ; 52 Week Low: $1.64.

The stock opens at $2.64, after a previous close of $2.63. The stock reached a daily high of $2.63 and a low of $2.56, with a 52-week high of $5.34 and a 52-week low of $1.64.

Can Indians buy Geron shares?

Yes, Indians can invest in the Geron (GERN) from India.

With INDmoney, you can buy Geron at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Geron at zero transaction cost.

How can I buy Geron shares from India?

It is very easy to buy Geron from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Geron (GERN) be purchased?

Yes, you can buy fractional shares of Geron with INDmoney app.

What are the documents required to start investing in Geron stocks?

To start investing in Geron, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.